Fig. 2From: RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancerMost recurrent mutations obtained from full exome data in a DWT and b RB1&TP53, please note that the figure does not include the RB1 HD present in several of the samples but not plotted. Hence, all samples shown in B) are co-altered and have RB1 alterationsBack to article page